



SAFETY DATA SHEET

Revision date 18-Jun-2022

Version 2

Page 1 / 13

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Bupivacaine Hydrochloride Injection (Hospira, Inc.)
Product Code(s) PZ03230
Synonyms Bupivacaine Spinal (Bupivacaine in Dextrose, USP)
Trade Name: MARCAINE; MARCAINE SPINAL
Chemical Family: Not determined

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used as anesthetic agent

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

Acute toxicity - Oral Category 4

2.2. Label elements

Signal word Warning

Hazard statements H302 - Harmful if swallowed

Precautionary Statements P264 - Wash hands thoroughly after handling
P270 - Do not eat, drink or smoke when using this product
P301 + P312 - IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell
P330 - Rinse mouth
P501 - Dispose of contents/container in accordance with all local and national regulations

SAFETY DATA SHEET

Product Name Bupivacaine Hydrochloride Injection (Hospira, Inc.)
Revision date 18-Jun-2022

Page 2 / 13
Version 2



2.3. Other hazards

Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances

Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Bupivacaine Hydrochloride (CAS #: 14252-80-3)	<= 0.75		Not Listed	Acute Tox. 2 (H300)	Not Listed	No data available	No data available
Sodium hydroxide (CAS #: 1310-73-2)	**	-	215-185-5	Skin Corr. 1A (H314)	Eye Irrit. 2 :: 0.5%<=C<2% Skin Corr. 1A :: C>=5% Skin Corr. 1B :: 2%<=C<5% Skin Irrit. 2 :: 0.5%<=C<2%	No data available	No data available
+ Hydrochloric Acid (CAS #: 7647-01-0)	**	-	231-595-7	Acute Tox. 3 (H331) Skin Corr. 1A (H314) Press. Gas	Eye Irrit. 2 :: 10%<=C<25% Skin Corr. 1B :: C>=25% Skin Irrit. 2 :: 10%<=C<25% STOT SE 3 :: C>=10%	No data available	No data available

NonHazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No.	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)

SAFETY DATA SHEET

Product Name Bupivacaine Hydrochloride Injection (Hospira, Inc.)
Revision date 18-Jun-2022

Page 3 / 13
Version 2

				1272/2008 [CLP]			
Methyl-p-hydroxybenzoate (CAS #: 99-76-3)	*		202-785-7	Not classified as hazardous	Not Listed	No data available	No data available
Dextrose (CAS #: 14431-43-7)	*		Not Listed	Not classified as hazardous	Not Listed	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate
No information available

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Bupivacaine Hydrochloride 14252-80-3	18	No data available	No data available	No data available	No data available
Sodium hydroxide 1310-73-2	325	1350	No data available	No data available	No data available
+ Hydrochloric Acid 7647-01-0	238	5010	No data available	No data available	563.3022

Additional information

* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret. Non-hazardous ingredients provided for completeness.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
Skin contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

SAFETY DATA SHEET

Product Name Bupivacaine Hydrochloride Injection (Hospira, Inc.)
Revision date 18-Jun-2022

Page 4 / 13
Version 2

5.1. Extinguishing media

Suitable Extinguishing Media Dry chemical, CO2, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical Not flammable.

Hazardous combustion products Formation of toxic gases is possible during heating or fire.

5.3. Advice for firefighters

Special protective equipment for fire-fighters Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s) Pharmaceutical drug product.

SAFETY DATA SHEET

Product Name Bupivacaine Hydrochloride Injection (Hospira, Inc.)
Revision date 18-Jun-2022

Page 5 / 13
Version 2

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Bupivacaine Hydrochloride

Pfizer OEL TWA-8 Hr: 20 $\mu\text{g}/\text{m}^3$

Methyl-p-hydroxybenzoate

Russia

MAC: 4 mg/m^3

Sodium hydroxide

ACGIH OEL (Ceiling)

2 mg/m^3

ACGIH TLV

Ceiling: 2 mg/m^3

Austria

2 mg/m^3

STEL 4 mg/m^3

Bulgaria

2.0 mg/m^3

Czech Republic

1 mg/m^3

Ceiling: 2 mg/m^3

Denmark

Ceiling: 2 mg/m^3

Estonia

1 mg/m^3

STEL: 2 mg/m^3

Finland

Ceiling: 2 mg/m^3

France

2 mg/m^3

Hungary

1 mg/m^3

STEL: 2 mg/m^3

Ireland

STEL: 2 mg/m^3

Ceiling Limit Value

2 mg/m^3

Latvia

0.5 mg/m^3

Poland

STEL: 1 mg/m^3

0.5 mg/m^3

Romania

1 mg/m^3

STEL: 3 mg/m^3

Slovakia

2 mg/m^3

Spain

STEL: 2 mg/m^3

Switzerland

2 mg/m^3

STEL: 2 mg/m^3

OSHA PEL

2 mg/m^3

(vacated) Ceiling: 2 mg/m^3

STEL: 2 mg/m^3

United Kingdom

+ Hydrochloric Acid

ACGIH OEL (Ceiling)

2 ppm

ACGIH TLV

Ceiling: 2 ppm

Austria

5 ppm

8 mg/m^3

STEL 10 ppm

STEL 15 mg/m^3

Bulgaria

STEL: 10 ppm

STEL: 15.0 mg/m^3

5 ppm

Czech Republic

8.0 mg/m^3

8 mg/m^3

Estonia

Ceiling: 15 mg/m^3

5 ppm

8 mg/m^3

STEL: 10 ppm

STEL: 15 mg/m^3

European Union

TWA: 5 ppm

TWA: 8 mg/m^3

STEL: 10 ppm

SAFETY DATA SHEET

Product Name Bupivacaine Hydrochloride Injection (Hospira, Inc.)
Revision date 18-Jun-2022

Page 6 / 13
Version 2

Finland	STEL: 15 mg/m ³ STEL: 5 ppm
Germany	STEL: 7.6 mg/m ³ 2 ppm 3.0 mg/m ³ Ceiling / Peak: 4 ppm Ceiling / Peak: 6 mg/m ³
Germany	2 ppm 3 mg/m ³
Hungary	8 mg/m ³
Ireland	STEL: 16 mg/m ³ 8 mg/m ³ 5 ppm STEL: 10 ppm
Italy	STEL: 15 mg/m ³ 5 ppm 8 mg/m ³ STEL: 10 ppm STEL: 15 mg/m ³
Ceiling Limit Value	2 ppm 3.0 mg/m ³
Latvia	5 ppm 8 mg/m ³ STEL: 10 ppm STEL: 15 mg/m ³
Netherlands	8 mg/m ³ STEL: 15 mg/m ³
Poland	STEL: 10 mg/m ³ 5 mg/m ³
Romania	5 ppm 8 mg/m ³ STEL: 10 ppm STEL: 15 mg/m ³
Russia	MAC: 5 mg/m ³
Slovakia	5 ppm 8.0 mg/m ³
Spain	5 ppm 7.6 mg/m ³ STEL: 10 ppm STEL: 15 mg/m ³
Switzerland	2 ppm 3 mg/m ³ STEL: 4 ppm STEL: 6 mg/m ³
U.S. - OSHA - Final PELs - Ceiling Limits	5 ppm 7 mg/m ³
OSHA PEL	(vacated) Ceiling: 5 ppm (vacated) Ceiling: 7 mg/m ³ Ceiling: 5 ppm Ceiling: 7 mg/m ³
United Kingdom	TWA: 1 ppm TWA: 2 mg/m ³ STEL: 5 ppm STEL: 8 mg/m ³

8.2. Exposure controls

Engineering controls

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

SAFETY DATA SHEET

Product Name Bupivacaine Hydrochloride Injection (Hospira, Inc.)
Revision date 18-Jun-2022

Page 7 / 13
Version 2

Environmental exposure controls	No information available.
Personal protective equipment	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.
Eye/face protection	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).
Hand protection	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).
Skin and body protection	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).
Respiratory protection	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)
General hygiene considerations	Handle in accordance with good industrial hygiene and safety practice.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state	Solution
Color	Clear, colorless
Odor	No information available.
Odor threshold	No information available
Molecular formula	Mixture
Molecular weight	Mixture
Property	Values
pH	No data available
Melting point / freezing point	No data available
Boiling point / boiling range	
Flash point	No information available
Evaporation rate	No data available
Flammability (solid, gas)	No data available
Flammability Limit in Air	
Upper flammability limit:	No data available
Lower flammability limit:	No data available
Vapor pressure	No data available
Vapor density	No data available
Relative density	No data available
Water solubility	No data available
Solubility(ies)	No data available
Partition coefficient	No data available
Autoignition temperature	No data available
Decomposition temperature	No data available

SAFETY DATA SHEET

Product Name Bupivacaine Hydrochloride Injection (Hospira, Inc.)
Revision date 18-Jun-2022

Page 8 / 13
Version 2

Kinematic viscosity	No data available
Dynamic viscosity	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available
Explosive properties	No information available

9.2. Other information

No information available

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No data available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

Sensitivity to Mechanical Impact No data available.

Sensitivity to Static Discharge No data available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information:	The information included in this section describes the potential hazards of the individual ingredients
Short term	May cause mild eye irritation. May cause slight skin irritation. (based on components). Anesthetic drug: may cause central nervous system and cardiovascular system effects
Known Clinical Effects:	Adverse effects associated with therapeutic use include dizziness, nervousness, agitation, drowsiness, apprehension, euphoria, blurred/double vision, slurred speech, tremors, convulsions, and seizure. Respiratory depression and arrest may follow. Other, more serious effects seen with IV use of this drug, particularly when it is administered rapidly, are cardiovascular collapse, central nervous system depression, and/or hypotension.
Acute toxicity	Based on available data, the classification criteria are not met.
Serious eye damage/eye irritation	Based on available data, the classification criteria are not met.
Skin corrosion/irritation	Based on available data, the classification criteria are not met.
Respiratory or skin sensitization	Based on available data, the classification criteria are not met.
STOT - single exposure	Based on available data, the classification criteria are not met.
STOT - repeated exposure	Based on available data, the classification criteria are not met.
Reproductive toxicity	Based on available data, the classification criteria are not met.

SAFETY DATA SHEET

Product Name Bupivacaine Hydrochloride Injection (Hospira, Inc.)
Revision date 18-Jun-2022

Page 9 / 13
Version 2

Germ cell mutagenicity Based on available data, the classification criteria are not met.
Carcinogenicity Based on available data, the classification criteria are not met.
Aspiration hazard Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

Bupivacaine Hydrochloride

Rabbit Oral LD50 18 mg/kg
Rat Para-periosteal LD50 6 mg/kg
Rat Subcutaneous LD50 43 mg/kg
Mouse Intravenous LD50 6.1 mg/kg

SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³
Rat Oral LD 50 3 g/kg
Mouse Oral LD 50 4 g/kg
Rabbit Dermal LD 50 > 10 g/kg

Methyl-p-hydroxybenzoate

Mouse Oral LD50 > 8 g/kg
Rat Oral LD 50 2100 mg/kg

Sodium hydroxide

Mouse IP LD50 40 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Sodium hydroxide	= 325 mg/kg (Rat)	= 1350 mg/kg (Rabbit)	-
+ Hydrochloric Acid	238 - 277 mg/kg (Rat)	> 5010 mg/kg (Rabbit)	= 1.68 mg/L (Rat) 1 h

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE

Skin irritation Rabbit Mild
Eye irritation Rabbit Mild

Methyl-p-hydroxybenzoate

Skin irritation Rabbit Non-irritating
Eye irritation Rabbit Slight
Skin Sensitization Guinea Pig Negative

Sodium hydroxide

Eye Irritation Rabbit Severe
Skin Irritation Rabbit Severe

+ Hydrochloric Acid

Skin irritation Severe
Eye irritation Severe

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Bupivacaine Hydrochloride

1 Month(s) Rabbit Subcutaneous 9 mg/kg LOAEL Central nervous system
1 Month(s) Dog Subcutaneous 9 mg/kg NOAEL None identified

Methyl-p-hydroxybenzoate

28 Day(s) Rat Oral 250 mg/kg/day NOAEL Gastrointestinal System, Spleen, Thymus

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Bupivacaine Hydrochloride

Prenatal & Postnatal Development Intravenous 0.6 mg/kg LOAEL Neonatal toxicity
Embryo / Fetal Development Rat Subcutaneous 13.3 mg/kg/day NOAEL Maternal Toxicity
Embryo / Fetal Development Rat Subcutaneous 40 mg/kg/day NOAEL Developmental toxicity
Embryo / Fetal Development Rabbit Subcutaneous 22.2 mg/kg/day NOAEL Maternal Toxicity
Embryo / Fetal Development Rabbit Subcutaneous 5.8 mg/kg/day NOAEL Developmental toxicity

SAFETY DATA SHEET

Product Name Bupivacaine Hydrochloride Injection (Hospira, Inc.)
Revision date 18-Jun-2022

Page 10 / 13
Version 2

Peri-/Postnatal Development Rat Subcutaneous 13.3 mg/kg/day NOEL Fetotoxicity

Methyl-p-hydroxybenzoate

Embryo / Fetal Development Rabbit Oral 300 mg/kg/day NOEL Maternal toxicity, Developmental toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Bupivacaine Hydrochloride

Mammalian Cell Mutagenicity Negative

Methyl-p-hydroxybenzoate

In Vivo Dominant Lethal Assay Rat Negative

+ Hydrochloric Acid

Bacterial Mutagenicity (Ames) *Salmonella* Negative

In Vivo Micronucleus Rat Negative

Carcinogenicity

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

+ Hydrochloric Acid

IARC

Group 3 (Not Classifiable)

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties No information available.

11.2.2. Other information

Other adverse effects

No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview:

Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

12.1. Toxicity

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Methyl-p-hydroxybenzoate

Oryzias latipes (Japanese Rice Fish) OECD LC50 96 hours 59.5 mg/L

Daphnia magna (Water Flea) ISO EC50 48 hours 11.2 mg/L

12.2. Persistence and degradability

Persistence and degradability

Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)

Methyl-p-hydroxybenzoate

OECD Activated sludge Ultimate (CO2 Evolution) 89 % After 28 Day(s) Ready

12.3. Bioaccumulative potential

Bioaccumulation

No information available.

12.4. Mobility in soil

Mobility in soil

No information available.

12.5. Results of PBT and vPvB assessment

SAFETY DATA SHEET

Product Name Bupivacaine Hydrochloride Injection (Hospira, Inc.)
Revision date 18-Jun-2022

Page 11 / 13
Version 2

PBT and vPvB assessment No information available.

Chemical name	PBT and vPvB assessment
Methyl-p-hydroxybenzoate	The substance is not PBT / vPvB
Sodium hydroxide	The substance is not PBT / vPvB PBT assessment does not apply
+ Hydrochloric Acid	The substance is not PBT / vPvB PBT assessment does not apply

12.6. Endocrine disrupting properties

Endocrine disrupting properties No information available.

12.7. Other adverse effects

No information available.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number: Not applicable
UN proper shipping name: Not applicable
Transport hazard class(es): Not applicable
Packing group: Not applicable
Environmental Hazard(s): Not applicable

Special precautions for user: Not applicable

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Bupivacaine Hydrochloride	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
Methyl-p-hydroxybenzoate	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present

SAFETY DATA SHEET

Product Name Bupivacaine Hydrochloride Injection (Hospira, Inc.)
 Revision date 18-Jun-2022

Page 12 / 13
 Version 2

EINECS	202-785-7
AICS	Present
Sodium hydroxide	
CERCLA/SARA Section 313 de minimus %	Not Listed
Hazardous Substances RQs	1000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	215-185-5
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5 Schedule 6
Dextrose	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
AICS	Present
+ Hydrochloric Acid	
CERCLA/SARA Section 313 de minimus %	1.0 %
Hazardous Substances RQs	5000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-595-7
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5 Schedule 6

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
Sodium hydroxide - 1310-73-2	Use restricted. See item 75.	
+ Hydrochloric Acid - 7647-01-0	Use restricted. See item 75.	

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

Chemical name	Lower-tier requirements (tons)	Upper-tier requirements (tons)
+ Hydrochloric Acid - 7647-01-0	25	250

Chemical name	EU - Biocides
+ Hydrochloric Acid - 7647-01-0	Product-type 2: Disinfectants and algacides not intended for direct application to humans or animals

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

SAFETY DATA SHEET

Product Name Bupivacaine Hydrochloride Injection (Hospira, Inc.)
Revision date 18-Jun-2022

Page 13 / 13
Version 2

AICS - Australian Inventory of Chemical Substances

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of H-Statements referred to under section 3

Acute toxicity, oral-Cat.2; H300 - Fatal if swallowed Skin corrosion/irritation-Cat.1A; Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage Acute toxicity, inhalation-Cat.3; H331 - Toxic if inhaled

Data Sources: Publicly available toxicity information. Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reason for revision Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 6 - Accidental Release Measures. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information.

Revision date 18-Jun-2022

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.